BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 31562779)

  • 1. Triage of low-grade squamous intraepithelial lesions using human papillomavirus messenger ribonucleic acid tests-A prospective population-based register study.
    Reinholdt K; Juul KE; Dehlendorff C; Munk C; Kjaer SK; Thomsen LT
    Acta Obstet Gynecol Scand; 2020 Feb; 99(2):204-212. PubMed ID: 31562779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immediate histopathologic follow-up of cervista and aptima high-risk HPV assays in women with LSIL cytology.
    Zhang H; Varma KR; Han M; Matsko J; Zhao C
    Cancer Cytopathol; 2018 Aug; 126(8):525-532. PubMed ID: 29797678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types.
    Verdoodt F; Szarewski A; Halfon P; Cuschieri K; Arbyn M
    Cancer Cytopathol; 2013 Dec; 121(12):675-87. PubMed ID: 23881840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL Pap smear.
    Molden T; Nygård JF; Kraus I; Karlsen F; Nygård M; Skare GB; Skomedal H; Thoresen SO; Hagmar B
    Int J Cancer; 2005 May; 114(6):973-6. PubMed ID: 15645423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triage of women with low-grade cervical lesions--HPV mRNA testing versus repeat cytology.
    Sørbye SW; Arbyn M; Fismen S; Gutteberg TJ; Mortensen ES
    PLoS One; 2011; 6(8):e24083. PubMed ID: 21918682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytology and human papillomavirus testing 6 to 12 months after ASCUS or LSIL cytology in organized screening to predict high-grade cervical neoplasia between screening rounds.
    Tropé A; Sjøborg KD; Nygård M; Røysland K; Campbell S; Alfsen GC; Jonassen CM
    J Clin Microbiol; 2012 Jun; 50(6):1927-35. PubMed ID: 22518869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [HPV E6 and E7 mRNA combined with HPV 16 and 18 or 45 genotyping testing as a means of cervical cancer opportunistic screening].
    Wang JJ; Dong J; Deng ZX; Wang PF; Zhang XX; Du Y
    Zhonghua Fu Chan Ke Za Zhi; 2019 May; 54(5):301-306. PubMed ID: 31154710
    [No Abstract]   [Full Text] [Related]  

  • 8. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.
    Arbyn M; Roelens J; Simoens C; Buntinx F; Paraskevaidis E; Martin-Hirsch PP; Prendiville WJ
    Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD008054. PubMed ID: 23543559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Presence of High-Risk HPV mRNA in Relation to Future High-Grade Lesions among High-Risk HPV DNA Positive Women with Minor Cytological Abnormalities.
    Johansson H; Bjelkenkrantz K; Darlin L; Dilllner J; Forslund O
    PLoS One; 2015; 10(4):e0124460. PubMed ID: 25893988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accuracy of Messenger RNA Human Papillomavirus Tests for Diagnostic Triage of Minor Cytological Cervical Lesions: A Systematic Review and Meta-Analysis.
    Macedo ACL; Bavaresco DV; Gonçalves JCN; Grande AJ; da Rosa MI
    Sex Transm Dis; 2019 May; 46(5):297-303. PubMed ID: 30985633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test.
    Benevolo M; Vocaturo A; Caraceni D; French D; Rosini S; Zappacosta R; Terrenato I; Ciccocioppo L; Frega A; Giorgi Rossi P
    J Clin Microbiol; 2011 Jul; 49(7):2643-50. PubMed ID: 21525231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3.
    Ovestad IT; Vennestrøm U; Andersen L; Gudlaugsson E; Munk AC; Malpica A; Feng W; Voorhorst F; Janssen EA; Baak JP
    Gynecol Oncol; 2011 Nov; 123(2):278-83. PubMed ID: 21835440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy.
    Arbyn M; Roelens J; Cuschieri K; Cuzick J; Szarewski A; Ratnam S; Reuschenbach M; Belinson S; Belinson JL; Monsonego J
    Int J Cancer; 2013 Jan; 132(1):101-8. PubMed ID: 22610699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology.
    Rijkaart DC; Heideman DA; Coupe VM; Brink AA; Verheijen RH; Skomedal H; Karlsen F; Morland E; Snijders PJ; Meijer CJ
    J Clin Microbiol; 2012 Jul; 50(7):2390-6. PubMed ID: 22553244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness study on human papillomavirus detection methods used in the cervical cancer screening programme.
    Nygård M; Røysland K; Campbell S; Dillner J
    BMJ Open; 2014 Jan; 4(1):e003460. PubMed ID: 24401720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human papillomavirus mRNA and DNA testing in women with atypical squamous cells of undetermined significance: A prospective cohort study.
    Thomsen LT; Dehlendorff C; Junge J; Waldstrøm M; Schledermann D; Frederiksen K; Kjaer SK
    Int J Cancer; 2016 Oct; 139(8):1839-50. PubMed ID: 27004595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triage of HR-HPV positive women with minor cytological abnormalities: a comparison of mRNA testing, HPV DNA testing, and repeat cytology using a 4-year follow-up of a population-based study.
    Persson M; Elfström KM; Brismar Wendel S; Weiderpass E; Andersson S
    PLoS One; 2014; 9(2):e90023. PubMed ID: 24587193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HPV E6/E7 mRNA testing is more specific than cytology in post-colposcopy follow-up of women with negative cervical biopsy.
    Sørbye SW; Arbyn M; Fismen S; Gutteberg TJ; Mortensen ES
    PLoS One; 2011; 6(10):e26022. PubMed ID: 21998748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of ProEx C and PreTect HPV-Proofer E6/E7 mRNA tests in comparison with the hybrid capture 2 HPV DNA test for triaging ASCUS and LSIL cytology.
    Alaghehbandan R; Fontaine D; Bentley J; Escott N; Ghatage P; Lear A; Coutlee F; Ratnam S
    Diagn Cytopathol; 2013 Sep; 41(9):767-75. PubMed ID: 23341349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer.
    Ratnam S; Coutlee F; Fontaine D; Bentley J; Escott N; Ghatage P; Gadag V; Holloway G; Bartellas E; Kum N; Giede C; Lear A
    J Clin Microbiol; 2011 Feb; 49(2):557-64. PubMed ID: 21147950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.